Cosmetic Supply Chain Transparency Act of 2021

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. S.476/H.R.5547 - Maintaining Investments in New Innovation Act. S.3131/H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022. H.R.2630/S.652, the SAFE Step Act; H.R.830/S.1375, the HELP Copays Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program

Client expense: $500,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.5539 - ORPHAN Cures Act. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022. H.R.2630/S.652, the SAFE Step Act; H.R.830/S.1375, the HELP Copays Act. Policies regarding copay accumulators and impact on rare disease patients.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES

Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. S.476 /H.R.5547 - Maintaining Investments in New Innovation (MINI) Act. S.3131/H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $50,000

Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.5539 - ORPHAN Cures Act. Medicaid Drug Rebate rule.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022. Legislation regarding the Orphan Drug Exemption with the Inflation Reduction Act of 2022. H.R.2630/S.652, the SAFE Step Act; H.R.830/S.1375, the HELP Copays Act. Legislation to improve education and care pathways for patients with rare kidney disease. Policies regarding copay accumulators and impact on rare disease patients.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022. Legislation to improve education and care pathways for patients with rare kidney disease. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. S.476 /H.R.5547 - Maintaining Investments in New Innovation (MINI) Act. S.3131/H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $50,000

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. S.476 /H.R.5547 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $50,000

Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES

Innovative payment methodologies for cell and gene therapies Issues related to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 5539 - The Optimizing Research Progress Hope And New Cures Act and the small molecule penalty, including H.R. 7174 - The Ensuring Pathways to Innovative Cures Act Issues related to the Medicaid Drug Rebate Program

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

H.R. 1350 - Camerons Law H.R. 1805 - Leos Law H.R. 5376 - Inflation Reduction Act of 2022 (117th) H.R. 5539 - ORPHAN Cures Act S. 1214 - RARE Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES

Innovative payment methodologies for cell and gene therapies Issues relating to value-based purchasing arrangements under the Medicaid program, including H.R. 2666 - The Medicaid VBPs for Patients Act Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to Federal health program coverage of medically necessary food for those with digestive and inherited metabolic disorders Issues related to implementation of Public Law No. 117-169 -The Inflation Reduction Act of 2022, specifically the orphan drug exclusion, including H.R. 5539 - the Optimizing Research Progress Hope And New Cures Act

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Issues related to the safety of cosmetics, counterfeit products; FDA OTC Monograph Reform implementation; FDA sunscreen regulation; H.R. ___, Cosmetic Safety Enhancement Act; S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act; S. 2100, Personal Care Products Safety Act; H.R. 2467, PFAS Action Act of 2021; H.R. 4800/S. 2546, Reef Safe Act; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5872, Natural Cosmetics Act; H.R. 2617, Consolidated Appropriations Act, 2023 - Modernization of Cosmetics Regulation Act (MoCRA) of 2022

Client expense: $360,000 · Firm income: Not reported

Issues related to the safety of cosmetics, counterfeit products; FDA OTC Monograph Reform implementation; FDA sunscreen regulation; H.R. ___, Cosmetic Safety Enhancement Act; S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act; S. 2100, Personal Care Products Safety Act; H.R. 2467, PFAS Action Act of 2021; H.R. 4800/S. 2546, Reef Safe Act; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5872, Natural Cosmetics Act; H.R. 2617, Consolidated Appropriations Act, 2023 - Modernization of Cosmetics Regulation Act (MoCRA) of 2022

Client expense: $360,000 · Firm income: Not reported

H.R. 1062, ACCESS 45Q Act; H.R. 1512, CLEAN future Act; H.R. 2159, RECYCLE Act; H.R. 2238, Break Free from Plastics Act 2021; H.R. 2617, Consolidated Appropriations Act, 2023; H.R. 3633, Greener Transportation for Communities Act; H.R. 3684, Infrastructure Investment and Jobs Act; H.R. 4253, To require the Administrator of the Environmental Protection Agency to promulgate a national primary drinking water regulation for chromium-6, and for other purposes; H.R. 4309, Clean Energy Innovation and Deployment Act of 2021; H.R. 4334, American Energy First Act; H.R. 4346, Supreme Court Security Funding Act of 2022 (CHIPS Provision) and Public Law 117-167; H.R. 4350, National Defense Authorization Act for FY 2022; H.R. 4372, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2022; H.R. 4427, Brownfields Redevelopment Tax Incentive Reauthorization Act of 2021; H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act FY2022; H.R. 4534, FAIR Transition and Competition Act; H.R. 4559, Department of Defense Climate Resiliency and Readiness Act; H.R. 4996, Ocean Shipping Reform Act of 2021; H.R. 5279, Defense Energy Efficiency Act; H.R. 5376, Inflation Reduction Act of 2022; H.R. 5389, REDUCE Act of 2021; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 6277, Ethylene is Essential for Chemistry and Manufacturing Act; H.R. 6562, CLEAR Act; H.R. 6787, Gas Prices Relief Act of 2022; H.R. 7810, Alan Reinstein Ban Asbestos Now Act of 2022; H.R. 7900, National Defense Authorization Act for FY2023; H.R. 8059, Recycling and Composting Accountability Act; H.R. 8183, Recycling Infrastructure and Accessibility Act; H.R. 8262, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2023; H.R. 8294, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023; H.R. 8991, Methane Emissions Research Act of 2022; H.R. 8992, Methane Super-Emitter Strategy Act of 2022; H.R. 8993, Methane Emissions Mitigation Research and Development Act; H.R. 9000, Hydrogen for Industry Act of 2022; H.R. 9087, TAP American Energy Act; H.R. 9388, Protecting Communities from Plastics Act; S. 231, PFAS Act; S. 749, American Innovation and Jobs Act; S. 923, RECYCLE Act of 2021; S. 984, Break Free from Plastics Act 2021; S. 1260, US Innovation and Competition Act of 2021; S. 1605, National Defense Authorization Act for FY2022; S. 1807, Clean H2 Production Act; S. 1945, IGNITE HBCU Excellence Act; S. 2085, Save Our Future Act; S. 2100, Personal Care Products Safety Act; S. 2183, Superfund Polluter Pays Restoration Act of 2021; S. 2324, Federal Permitting Reform and Jobs Act; S. 2645, REDUCE Act of 2021; S. 2792, National Defense Authorization Act for FY2022; S. 3034, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2022; S. 3112, Hydrogen for Industry Act of 2021; S. 3305, Chemical Tax Repeal Act; S. 3609, Gas Prices Relief Act of 2022; S. 3742, Recycling Infrastructure and Accessibility Act; S. 3743, Recycling and Composting Accountability Act; S. 4244, Alan Reinstein Ban Asbestos Now Act of 2022; S. 4316, Ensuring Safe and Toxic-Free Foods Act of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; S. 4355, Clean Competition Act; S. 4543, James Inhofe National Defense Authorization Act for FY 2023; S. 4829, PFAS Intergovernmental Coordination Act; S. 5163, Protecting Communities from Plastics Act; 86Fed.Reg. 50296, Advance Notice of Proposed Rulemaking for Pyrolysis and Gasification Units; 87Fed.Reg. 40476, Advanced Notice of Proposed Rulemaking for Single-Use Plastics and Packaging; S.Res.304, A resolution designation July 2021 as "Plastic Pollution Action Month"; S.J.Res.14, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Oil and Natural Gas Sector: Emission Standards for New, Reconstructed, and Modified Sources Review"; FY2022 Department of the Interior, Environment, and Related Agencies Appropriations; FY2023 EPA Appropriations; FY2022 Senate Inter-Environment Appropriations bill; FY2023 Department of the Interior, Environment and Related Agencies Appropriations Act; FY2023 Senate National Defense Authorization Act; Unintroduced Advanced Recycling, Recycling Content, and Recycling Standard; Unintroduced legislation regarding actions for sustainable change; Unintroduced legislation related to the Pesticide Registration Improvement Act; EO 14057, Executive Order Catalyzing Americas Clean Energy Economy Through Federal Sustainability; Chemical Management; Climate policy/carbon emissions reduction; FDA recycled content in food contact packaging; FIFRA Registration Review; Formaldehyde IRIS assessment; Innovative Materials for America's Growth and Infrastructure Newly Expanded (IMAGINE) Act; Nominations of Stephen A. Owens and Catherine J.K. Sandoval to the Chemical Safety and Hazard Investigation Board (CSB); PFAS Action Plan Issues; Regulation of Asbestos; Risk Management Plan Rulemaking; Spray Foam Policy; Superfund Tax; The Recycling Partnership's Producer Responsibility Legislation; The use of advanced materials in infrastructure; TSCA Implementation

H.R. 257, INVEST Act; H.R. 507, Innovative Energy Manufacturing Act of 2021; H.R. 848, GREEN Act of 2021; H.R. 1062, ACCESS 45Q Act; H.R. 3294, IGNITE HBCU Excellence Act; H.R. 4153, Clean Energy Future Through Innovation Act of 2021; H.R. 4309, Clean Energy Innovation and Deployment Act of 2021; H.R. 4334, American Energy First Act; H.R. 4346, Supreme Court Security Funding Act of 2022 (CHIPS Provision); H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act FY2022; H.R. 4521, US Innovation and Competition Act of 2021; H.R. 4534, FAIR Transition and Competition Act; H.R. 4559, Department of Defense Climate Resiliency and Readiness Act; H.R. 5279, Defense Energy Efficiency Act; H.R. 5376, Inflation Reduction Act of 2022; H.R. 5389, REDUCE Act OF 2021; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5673, Safeguarding Tomorrow through Ongoing Risk Mitigation Technical Correction Act; H.R. 6546, Wireless Electric Vehicle Charging Grant Program Act of 2022; H.R. 6562, CLEAR Act; H.R. 6680, Blue Energy Innovation Act of 2022; H.R. 7155, Home Front Energy Independence Act; H.R. 7439, Energy Security and Independence Act of 2022; H.R. 8059, Recycling and Composting Accountability Act; H.R. 8183, Recycling Infrastructure and Accessibility Act; H.R. 8255, Energy and Water Development and Related Agencies Appropriations Act, 2023; H.R. 8966, START Act; H.R. 9000, Hydrogen for Industry Act of 2022; H.R. 9087, TAP American Energy Act; S. 1034, Financing Our Energy Future Act; S. 1298, Clean Energy for America Act; S. 2118, Clean Energy for America Act; S. 2501, Offshore Wind Jobs and Opportunity Act; S. 2645, REDUCE Act OF 2021; S. 3034, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2022; S. 3112, Hydrogen for Industry Act of 2021; S. 3543, Vehicle Innovation Act of 2022; S. 3787, Home Front Energy Independence Act; S. 4013, Energy Security and Independence Act of 2022; S. 4543, James Inhofe National Defense Authorization Act for FY 2023; S. 4815, START Act; S.J.Res.14, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Oil and Natural Gas Sector: Emission Standards for New, Reconstructed, and Modified Sources Review"; FY2022 Department of the Interior, Environment, and Related Agencies Appropriations; FY2023 Department of the Interior, Environment and Related Agencies Appropriations Act; EO 14057, Executive Order Catalyzing Americas Clean Energy Economy Through Federal Sustainability; Alternative Fuel Policy; Automotive Plastics; Clean Energy Future through Innovation Act of 2021; Clean Energy Innovation and Deployment Act; Energy Efficiency and Recovery; Green Building Policy; Natural Gas Policy; Plastics Recycling and Innovation

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the Consolidated Appropriations Act, 2023 (H.R.2617), FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R.2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).

Client expense: Not reported · Firm income: $10,000

H.R. 257, INVEST Act; H.R. 507, Innovative Energy Manufacturing Act of 2021; H.R. 848, GREEN Act of 2021; H.R. 1062, ACCESS 45Q Act; H.R. 3294, IGNITE HBCU Excellence Act; H.R. 4153, Clean Energy Future Through Innovation Act of 2021; H.R. 4309, Clean Energy Innovation and Deployment Act of 2021; H.R. 4334, American Energy First Act; H.R. 4346, Supreme Court Security Funding Act of 2022 (CHIPS Provision); H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act FY2022; H.R. 4521, US Innovation and Competition Act of 2021; H.R. 4534, FAIR Transition and Competition Act; H.R. 4559, Department of Defense Climate Resiliency and Readiness Act; H.R. 5279, Defense Energy Efficiency Act; H.R. 5376, Inflation Reduction Act of 2022; H.R. 5389, REDUCE Act OF 2021; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 5673, Safeguarding Tomorrow through Ongoing Risk Mitigation Technical Correction Act; H.R. 6546, Wireless Electric Vehicle Charging Grant Program Act of 2022; H.R. 6562, CLEAR Act; H.R. 6680, Blue Energy Innovation Act of 2022; H.R. 7155, Home Front Energy Independence Act; H.R. 7439, Energy Security and Independence Act of 2022; H.R. 8059, Recycling and Composting Accountability Act; H.R. 8183, Recycling Infrastructure and Accessibility Act; H.R. 8255, Energy and Water Development and Related Agencies Appropriations Act, 2023; H.R. 8966, START Act; H.R. 9087, To Restart Onshore and Offshore Oil and Gas Leasing, Streamline Permitting for Energy Infrastructure, Ensure Transparency in Energy Development on Federal lands, and for Other Purposes; S. 1034, Financing Our Energy Future Act; S. 1298, Clean Energy for America Act; S. 2118, Clean Energy for America Act; S. 2501, Offshore Wind Jobs and Opportunity Act; S. 2645, REDUCE Act OF 2021; S. 3034, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2022; S. 3543, Vehicle Innovation Act of 2022; S. 3787, Home Front Energy Independence Act; S. 4013, Energy Security and Independence Act of 2022; S. 4543, James Inhofe National Defense Authorization Act for FY 2023; S. 4815, START Act; S.J.Res.14, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Oil and Natural Gas Sector: Emission Standards for New, Reconstructed, and Modified Sources Review"; FY2022 Department of the Interior, Environment, and Related Agencies Appropriations; FY2023 Department of the Interior, Environment and Related Agencies Appropriations Act; EO 14057, Executive Order Catalyzing Americas Clean Energy Economy Through Federal Sustainability; Alternative Fuel Policy; Automotive Plastics; Clean Energy Future through Innovation Act of 2021; Clean Energy Innovation and Deployment Act; Energy Efficiency and Recovery; Green Building Policy; Natural Gas Policy; Plastics Recycling and Innovation

H.R. 1062, ACCESS 45Q Act; H.R. 1512, CLEAN future Act; H.R. 2159, RECYCLE Act; H.R. 2238, Break Free from Plastics Act 2021; H.R. 3633, Greener Transportation for Communities Act; H.R. 3684, Infrastructure Investment and Jobs Act; H.R. 4253, To require the Administrator of the Environmental Protection Agency to promulgate a national primary drinking water regulation for chromium-6, and for other purposes; H.R. 4309, Clean Energy Innovation and Deployment Act of 2021; H.R. 4334, American Energy First Act; H.R. 4346, Supreme Court Security Funding Act of 2022 (CHIPS Provision); H.R. 4350, National Defense Authorization Act for FY 2022; H.R. 4372, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2022; H.R. 4427, Brownfields Redevelopment Tax Incentive Reauthorization Act of 2021; H.R. 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act FY2022; H.R. 4534, FAIR Transition and Competition Act; H.R. 4559, Department of Defense Climate Resiliency and Readiness Act; H.R. 4996, Ocean Shipping Reform Act of 2021; H.R. 5279, Defense Energy Efficiency Act; H.R. 5376, Inflation Reduction Act of 2022; H.R. 5389, REDUCE Act of 2021; H.R. 5537, Toxic-free Beauty Act of 2021; H.R. 5538, Cosmetic Fragrance and Flavor Ingredient Right to know Act of 2021; H.R. 5539, Cosmetic Supply Chain Transparency Act of 2021; H.R. 5540, Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021; H.R. 6277, Ethylene is Essential for Chemistry and Manufacturing Act; H.R. 6562, CLEAR Act; H.R. 6787, Gas Prices Relief Act of 2022; H.R. 7810, Alan Reinstein Ban Asbestos Now Act of 2022; H.R. 7900, National Defense Authorization Act for FY2023; H.R. 8059, Recycling and Composting Accountability Act; H.R. 8183, Recycling Infrastructure and Accessibility Act; H.R. 8262, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2023; H.R. 8294, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023; H.R. 8991, Methane Emissions Research Act of 2022; H.R. 8992, Methane Super-Emitter Strategy Act of 2022; H.R. 8993, Methane Emissions Mitigation Research and Development Act; H.R. 9087, To Restart Onshore and Offshore Oil and Gas Leasing, Streamline Permitting for Energy Infrastructure, Ensure Transparency in Energy Development on Federal lands, and for Other Purposes; S. 749, American Innovation and Jobs Act; S. 923, RECYCLE Act of 2021; S. 984, Break Free from Plastics Act 2021; S. 1260, US Innovation and Competition Act of 2021; S. 1605, National Defense Authorization Act for FY2022; S. 1807, Clean H2 Production Act; S. 1945, IGNITE HBCU Excellence Act; S. 2085, Save Our Future Act; S. 2100, Personal Care Products Safety Act; S. 2183, Superfund Polluter Pays Restoration Act of 2021; S. 2324, Federal Permitting Reform and Jobs Act; S. 2645, REDUCE Act of 2021; S. 2792, National Defense Authorization Act for FY2022; S. 3034, Department of the Interior, Environment, and Related Agencies Appropriations Act FY2022; S. 3305, Chemical Tax Repeal Act; S. 3609, Gas Prices Relief Act of 2022; S. 3742, Recycling Infrastructure and Accessibility Act; S. 3743, Recycling and Composting Accountability Act; S. 4244, Alan Reinstein Ban Asbestos Now Act of 2022; S. 4316, Ensuring Safe and Toxic-Free Foods Act of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; S. 4355, Clean Competition Act; S. 4543, James Inhofe National Defense Authorization Act for FY 2023; S. 4829, PFAS Intergovernmental Coordination Act; 86Fed.Reg. 50296, Advance Notice of Proposed Rulemaking for Pyrolysis and Gasification Units; 87Fed.Reg. 40476, Advanced Notice of Proposed Rulemaking for Single-Use Plastics and Packaging; S.Res.304, A resolution designation July 2021 as "Plastic Pollution Action Month"; S.J.Res.14, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Oil and Natural Gas Sector: Emission Standards for New, Reconstructed, and Modified Sources Review"; FY2022 Department of the Interior, Environment, and Related Agencies Appropriations; FY2023 EPA Appropriations; FY2022 Senate Inter-Environment Appropriations bill; FY2023 Department of the Interior, Environment and Related Agencies Appropriations Act; FY2023 Senate National Defense Authorization Act; Unintroduced Advanced Recycling, Recycling Content, and Recycling Standard; Unintroduced legislation regarding actions for sustainable change; Unintroduced legislation related to the Pesticide Registration Improvement Act; EO 14057, Executive Order Catalyzing Americas Clean Energy Economy Through Federal Sustainability; Chemical Management; Climate policy/carbon emissions reduction; FDA recycled content in food contact packaging; FIFRA Registration Review; Formaldehyde IRIS assessment; Innovative Materials for America's Growth and Infrastructure Newly Expanded (IMAGINE) Act; PFAS Action Plan Issues; Regulation of Asbestos; Risk Management Plan Rulemaking; Spray Foam Policy; Superfund Tax; The Recycling Partnership's Producer Responsibility Legislation; The use of advanced materials in infrastructure; TSCA Implementation

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education and lobbying activities to improve the health and environmental safety of personal care products and to strengthen supply chain transparency and safety for personal care products, including the FDASLA Act of 2022 (S.4348), Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S. 2047), PFAS Action Act of 2021 (H.R. 2467), Natural Cosmetics Act (H.R. 5872), Personal Care Product Safety Act (S. 2100).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE